BXRX - Baudax Bio Inc Stock Price, Fair Value and News

$0.010.00 (0.00%)

Market Closed

BXRX Stock Valuation Analysis

Valuation

Max Portfolio %

BXRX Price Action

BXRX RSI Chart

BXRX Stock Valuation Analysis

Valuation

Max Portfolio %

BXRX Valuation

BXRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

BXRX Fundamentals

BXRX Revenue

BXRX Earnings

BXRX Profitability

BXRX Investor Care

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	1.3M	1.4M	1.4M	1.3M
2021	639.8K	786.5K	933.3K	1.1M
2020	0	0	0	493.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Baudax Bio Inc

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania.

CEO	Dr. Geraldine A. Henwood Ph.D.
WEBSITE	baudaxbio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	9